Activin-A, myostatin and interleukin-6 in cancer associated cachexia
Cachexia is a muscle wasting condition associated with multiple different chronic illnesses, such as cancer, diabetes and AIDS. In cancer, approximately 80% of patients with advanced disease have symptoms of muscle wasting, and around 25% of cancer mortality concerns cachexia. Elevated serum levels of different cytokines and TGF-β protein family members, such as Interleukin-6, Myostatin and Activin-A, have been observed in cachetic patients and test animals. However, the mechanistic role and the relative contribution of these molecules to muscle loss in the syndrome have not yet been fully elucidated. In this thesis, the gene-expression levels of Activin-A, Myostatin and Interleukin-6 was assessed with Reverse-Transcriptase quantitative PCR from the tumor and muscle tissue of cachetic C26-tumor-bearing mice to clarify whether they arise from the tumor or are muscle derived. Additionally, transfection of CAGA-luciferase plasmid construct was optimized for the C2C12 murine myoblast cell-line to be utilized in research concerning TGF-β mediated cancer-associated cachexia in vitro. The function of the construct was tested by administration of exogenous Activin-A, with and without its inhibitor, into the C2C12 growth media. This thesis showed a marked increase in the expression levels of Activin-A (inhibin-βA) and IL-6 mRNA in cachexia inducing tumors (C26) when compared to tumors not inducing cachexia (Lewis-Lung-Cancer) (P < 0.001). Additionally, the results show decrease in muscle-derived Activin-A (inhibin-βA) in the cachetic groups (P < 0.05). These results imply that Activin-A and Interleukin-6 are strongly induced in the tumors that produced cachexia in vivo. This work also presents a successful, optimized plasmid transfection protocol for the notoriously transfection resistant C2C12-myoblast cell line. The presented in vitro –method can partially replace animal tests in related settings, when studying the mechanistic effects of cachexia-inducing TGF-β proteins on muscle tissue.
...
Keywords
Metadata
Show full item recordCollections
- Pro gradu -tutkielmat [29107]
Related items
Showing items with similar title or keywords.
-
Blocking Activin Receptor Ligands Is Not Sufficient to Rescue Cancer-Associated Gut Microbiota : A Role for Gut Microbial Flagellin in Colorectal Cancer and Cachexia?
Pekkala, Satu; Keskitalo, Anniina; Kettunen, Emilia; Lensu, Sanna; Nykänen, Noora; Kuopio, Teijo; Ritvos, Olli; Hentilä, Jaakko; Nissinen, Tuuli A.; Hulmi, Juha J. (MDPI AG, 2019)Colorectal cancer (CRC) and cachexia are associated with the gut microbiota and microbial surface molecules. We characterized the CRC-associated microbiota and investigated whether cachexia affects the microbiota composition. ... -
Treating cachexia using soluble ACVR2B improves survival, alters mTOR localization, and attenuates liver and spleen responses
Nissinen, Tuuli; Hentilä, Jaakko; Penna, Fabio; Lampinen, Anita; Lautaoja, Juulia; Fachada, Vasco; Holopainen, Tanja; Ritvos, Olli; Kivelä, Riikka; Hulmi, Juha (Wiley, 2018)Background Cancer cachexia increases morbidity and mortality, and blocking of activin receptor ligands has improved survival in experimental cancer. However, the underlying mechanisms have not yet been fully uncovered. ... -
Muscle NAD+ depletion and Serpina3n as molecular determinants of murine cancer cachexia : the effects of blocking myostatin and activins
Hulmi, J.; Penna, F.; Pöllänen, N.; Nissinen, T.; Hentilä, J.; Euro, L.; Lautaoja, J.; Ballarò, R.; Soliymani, R.; Baumann, M.; Ritvos, O.; Pirinen, E.; Lalowski, M. (Elsevier, 2020)Objective Cancer cachexia and muscle loss are associated with increased morbidity and mortality. In preclinical animal models, blocking activin receptor (ACVR) ligands has improved survival and prevented muscle wasting in ... -
Activin Receptor Ligand Blocking and Cancer Have Distinct Effects on Protein and Redox Homeostasis in Skeletal Muscle and Liver
Hentilä, Jaakko; Nissinen, Tuuli; Korkmaz, Ayhan; Lensu, Sanna; Silvennoinen, Mika; Pasternack, Arja; Ritvos, Olli; Atalay, Mustafa; Hulmi, Juha (Frontiers Research Foundation, 2019)Muscle wasting in cancer cachexia can be alleviated by blocking activin receptor type 2 (ACVR2) ligands through changes in protein synthesis/degradation. These changes in cellular and protein metabolism may alter protein ... -
Molecular and physiological effects of muscle wasting and its treatment by blocking myostatin and activins
Nissinen, Tuuli (Jyväskylän yliopisto, 2020)Muscle wasting, occurring e.g. in cancer, is associated with poor prognosis, and cancer treatments may even exacerbate the wasting. The prevention of muscle wasting has improved survival in preclinical cancer models, but ...